Kalaris Therapeutics Reports Key Corporate Changes
Ticker: KLRS · Form: 8-K · Filed: Mar 18, 2025 · CIK: 1754068
| Field | Detail |
|---|---|
| Company | Kalaris Therapeutics, Inc. (KLRS) |
| Form Type | 8-K |
| Filed Date | Mar 18, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition-disposition, corporate-governance, financial-reporting
Related Tickers: KLRS
TL;DR
Kalaris Therapeutics (KLRS) filed an 8-K detailing asset changes, operational results, and executive shifts.
AI Summary
Kalaris Therapeutics, Inc. filed an 8-K on March 18, 2025, reporting on several key events including the completion of an acquisition or disposition of assets, results of operations, changes in control, officer and director changes, amendments to its articles of incorporation, and a change in shell company status. The company, formerly known as Allovir, Inc. and ViraCyte, Inc., is in the biological products sector.
Why It Matters
This 8-K filing indicates significant corporate restructuring and operational updates for Kalaris Therapeutics, potentially impacting its strategic direction and financial reporting.
Risk Assessment
Risk Level: medium — The filing covers multiple significant corporate events, including potential changes in control and asset dispositions, which warrant closer examination.
Key Players & Entities
- Kalaris Therapeutics, Inc. (company) — Registrant
- Allovir, Inc. (company) — Former Company Name
- ViraCyte, Inc. (company) — Former Company Name
- 2836 (dollar_amount) — Standard Industrial Classification Code
FAQ
What specific assets were involved in the completion of an acquisition or disposition of assets?
The filing does not specify the details of the acquisition or disposition of assets, only that it is a reported item.
What were the key results of operations and financial condition reported?
The filing lists 'Results of Operations and Financial Condition' as an item, but does not provide specific financial details within this 8-K summary.
What changes in control of the registrant were reported?
The filing indicates a 'Changes in Control of Registrant' item, but the specifics are not detailed in the provided text.
Were there any departures or appointments of directors or officers?
Yes, the filing includes 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' as a reported item.
Did Kalaris Therapeutics change its shell company status?
Yes, the filing explicitly lists 'Change in Shell Company Status' as one of the reported items.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 18, 2025 regarding Kalaris Therapeutics, Inc. (KLRS).